Find intellectual property law content faster
Wolters Kluwer continues to provide authoritative, accurate, and timely analysis and resources to support your business entities law practice. Cheetah™ Intellectual Property Law gives you access to topic segments that include Copyright, Trademark and Advertising, Patent, and Technology and Internet.
Expert analysis and authoritative content
Leading authorities provide the insights you need including international coverage of patent and trademark requirements in over 230 jurisdictions around the world written by attorneys from each country.
Easy to use practice tools
Utilize Searchable Content and Smart Charts to access forms, checklists and practice tips to do fast, accurate preliminary research, comparing jurisdictions in easy-to-read charts that provide detailed summaries and links for further analysis.
IP Law Daily, news alerts, and international blog posts keep you on top of developments, ensuring you’re able to advise clients on how changes in the law might affect them.
Explore the types of articles and in-depth analysis available through the IP Law Daily.
Weight loss drug patent claims invalid as obvious
Although the patents covering Contrave® contained an adequate written description, the weight loss properties of the drug were well known to the industry prior to the issuance of the patent.
Misappropriation and correction of inventorship claims in sensor patent dispute properly dismissed
Federal Circuit affirms that trade secret claims cannot be backdated to subsequent discoveries of misappropriation.
Patent infringement claims brought by gaming machine developer transferred
Under TC Heartland, New Jersey was not a proper venue for patent claims asserted by High 5 Games.
Court affirms validity of Amgen’s patents for rheumatoid arthritis drug Enbrel
The court concluded the patent claims are not invalid based on challenges for lack of written description and obviousness.
Proposed chemotherapy treatment methods infringed Alimta patent under doctrine of equivalents
A ruling that Hospira’s proposed drug literally infringed Eli Lilly’s patent was reversed, but Hospira’s and Dr. Reddy’s use of pemetrexed ditromethamine was not substantially...